CID 160051

Base Information

• Chemical Name: CID 160051
• CAS No.: 182815-44-7
• Molecular Formula: (C13H27N)n^.(C12H27ClN2)n^.(C3H7N)n^.(C3H5ClO)n^.xHCl
• Molecular Weight: 618.24900
• Wikidata: Q899036
• NCI Thesaurus Code: C28937
• RXCUI: 141625
• Mol file: 182815-44-7.mol

Synonyms:31104, GT;CholestaGel;colesevelam;Colesevelam HCl;colesevelam hydrochloride;GT 31104;GT-31104;GT31 104;GT31-104;GT31104;HCl, Colesevelam;Hydrochloride, Colesevelam;Welchol

Chemical Property of CID 160051

Chemical Property:

• PSA: 62.61000
• LogP: 5.97450
• Hydrogen Bond Donor Count: 4
• Hydrogen Bond Acceptor Count: 5
• Rotatable Bond Count: 22
• Exact Mass: 616.438046
• Heavy Atom Count: 39
• Complexity: 301

Purity/Quality:

99% ^*data from raw suppliers

ColesevelamHydrochloride(TechnicalGrade) ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Drug Classes: Antilipemic Agents
• Canonical SMILES: CCCCCCCCCCNCC=C.C[N+](C)(C)CCCCCCNCC=C.C=CCN.C1C(O1)CCl.Cl.[Cl-]
• Recent ClinicalTrials: Trial to Evaluate Diarrhoea Discontinuations at 3 Cycles in Patients With Early-stage HER2+, HR+ Breast Cancer Treated With Neratinib Plus Loperamide Versus Neratinib Dose Escalation Plus Loperamide Administered as Needed Versus Neratinib Plus Loperamide Plus Colesevelam (DIANER)
• Recent EU Clinical Trials: A Randomized Phase II Study to Evaluate the Incidence of Discontinuations due to Diarrhoea at 3 Cycles in patients with Early-stage HER2-positive (HER2+), Hormone Receptor-positive (HR+) Breast Cancer treated with Neratinib plus Loperamide prophylaxis versus Neratinib with Initial Dose Escalation plus PRN Loperamide prophylaxis versus Neratinib plus Loperamide plus Colesevelam prophylaxis. “DIANER Study”
• Description: Colesevelam hydrochloride was launched as Welchol (formerly known as Cholestagel) in the US for the reduction of elevated levels of serum LDL cholesterol and accordingly, the decrease of the risk of vascular disease in patients with primary hypercholesterolemia. This orally administered cationic hydrogel is a non-absorbable, water-insoluble polymer of an hexanaminium chloride with N-(2-propenyl) decanamine, 2-propen-1-amine hydrochloride and chloromethyloxirane. It acts as a powerful bile acid sequestering agent, this binding and blockage of bile acids having the end result of compelling the removal of LDL cholesterol from the blood stream into the liver. In animals fed with a cholesterol-rich diet for several weeks, colesevelam demonstrated a good maintenance of low serum cholesterol levels, this activity being significantly greater when compared with cholestyramine. In several placebo-controlled studies, this agent decreased total cholesterol levels by 6 to 10% and LDL cholesterol levels by 9 to 20%. Combination therapy with the co-administration of a HMG-CoA reductase inhibitor (or statin) and colesevelam produced an additional reduction of 8-16% in LDL-cholesterol levels above that obtained with the statin alone. Due to its unique water-absorbing hydrogel formulation, this polymer is not absorbed at all from the GI tract, and thus, it is said to have a lower rate of side-effects (as the constipating effect) than the previously marketed bile acid sequestrants. Colesevelam hydrochloride may be used as a monotherapy or as a dual therapy with statins.
• Uses: Colesevelam Hydrochloride is used to reduce elevated low-density lipoprotein (LDL) cholesterol in patients with primary hyperlipidemia as well as to improve glycemic control in patients with type 2 diabetes. antibacterial
• Clinical Use: #N/A
• Drug interactions: Potentially hazardous interactions with other drugs Antidiabetic agents: absorption of glipizide, glibenclamide and glimepiride reduced, administer at least 4 hours before colesevelam; metformin extended release exposure increased, monitor carefully. Ciclosporin: may reduce absorption of ciclosporin. Olmesartan: absorption of olmesartan reduced, administer at least 4 hours before colesevelam.